Summary
1.34 0.01(0.76%)05/13/2024
Marinus Pharmaceuticals Inc (MRNS)
Marinus Pharmaceuticals Inc (MRNS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 5.72 | 12.54 | -80.85 | -84.18 | -75.88 | -82.86 | -91.72 | -95.09 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.57 | |
| Open | 1.47 | |
| High | 1.57 | |
| Low | 1.45 | |
| Volume | 1,152,088 | |
| Change | 0.09 | |
| Change % | 5.72 | |
| Avg Volume (20 Days) | 2,251,104 | |
| Volume/Avg Volume (20 Days) Ratio | 0.51 | |
| 52 Week Range | 1.11 - 11.26 | |
| Price vs 52 Week High | -86.06% | |
| Price vs 52 Week Low | 41.44% | |
| Range | 6.80 | |
| Gap Up/Down | -0.14 | |
Fundamentals | ||
| Market Capitalization (Mln) | 73 | |
| EBIDTA | -129,387,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.50 | |
| Book Value | -0.2990 | |
| Earnings Per Share | -2.6300 | |
| EPS Estimate Current Quarter | -0.6600 | |
| EPS Estimate Next Quarter | -0.6000 | |
| EPS Estimate Current Year | -2.0700 | |
| EPS Estimate Next Year | -1.1400 | |
| Diluted EPS (TTM) | -2.6300 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -4.6648 | |
| Return on asset (TTM) | -0.4611 | |
| Return on equity (TTM) | -4.2343 | |
| Revenue TTM | 28,288,000 | |
| Revenue per share TTM | 0.5140 | |
| Quarterly Revenue Growth (YOY) | -0.2600 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -55,943,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 24.5740 | |
| Revenue Enterprise Value | 10.8246 | |
| EBITDA Enterprise Value | -2.6729 | |
| Shares | ||
| Shares Outstanding | 54,931,000 | |
| Shares Float | 38,490,447 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 0.97 | |
| Institutions (%) | 106.10 | |
05/08 09:31 EST - Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago.
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago.
04/16 12:51 EST - Zacks Investment Research
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
04/15 12:54 EST - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
04/15 12:06 EST - InvestorPlace
Why Are Stocks Up Today?
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected.
Why Are Stocks Up Today?
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected.
04/15 11:30 EST - InvestorPlace
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Marinus Pharmaceuticals (NASDAQ: MRNS ) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It's bad news for MRNS stockholders today as the Phase 3 trail of intravenous ganaxolone as a treatment for refractory status epilepticus (RSE) failed to meet expectations.
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Marinus Pharmaceuticals (NASDAQ: MRNS ) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It's bad news for MRNS stockholders today as the Phase 3 trail of intravenous ganaxolone as a treatment for refractory status epilepticus (RSE) failed to meet expectations.
03/05 21:29 EST - Seeking Alpha
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript
Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript
Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET
03/05 18:11 EST - Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.76 per share a year ago.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.76 per share a year ago.
01/22 11:00 EST - Zacks Investment Research
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.
11/07 14:00 EST - Seeking Alpha
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - COO, CFO & Treasurer Thomas Lyons - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Joseph Thome - TD Cowen Joon Lee - Truist Securities Andrew Tsai - Jefferies Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Operator Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call.
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - COO, CFO & Treasurer Thomas Lyons - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Joseph Thome - TD Cowen Joon Lee - Truist Securities Andrew Tsai - Jefferies Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Operator Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call.
10/24 07:01 EST - Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus'.
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus'.
09/21 16:00 EST - Business Wire
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference. The fireside chat will take place on Thursday, September 28 beginning at 10:55 a.m. Eastern Time. A link to the event can be accessed on the.
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference. The fireside chat will take place on Thursday, September 28 beginning at 10:55 a.m. Eastern Time. A link to the event can be accessed on the.
09/20 10:31 EST - Zacks Investment Research
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
09/20 10:31 EST - Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
09/19 15:57 EST - Proactive Investors
Marinus Pharmaceuticals stock surges on financial guidance
Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders revealed highlights from its Investor and Analyst Event in New York. Marinus said it expects third quarter 2023 ZTALMY (ganaxolone) oral suspension CV net product revenues of between $5 million and $5.2 million and is on track to meet full year 2023 expected ZTALMY net product revenues of between $17 million and $18.5 million.
Marinus Pharmaceuticals stock surges on financial guidance
Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders revealed highlights from its Investor and Analyst Event in New York. Marinus said it expects third quarter 2023 ZTALMY (ganaxolone) oral suspension CV net product revenues of between $5 million and $5.2 million and is on track to meet full year 2023 expected ZTALMY net product revenues of between $17 million and $18.5 million.
07/27 07:01 EST - Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' websit.
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' websit.
07/03 05:27 EST - Zacks Investment Research
Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?
Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?
Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
06/22 17:55 EST - Seeking Alpha
Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade)
Marinus Pharmaceuticals has pivoted from postpartum depression to focus on seizure disorders, leading to FDA approval for Ztalmy (ganaxolone) for treating Cyclin-dependent Kinase-like 5 Deficiency Disorder (CDD) seizures. The company is exploring ganaxolone's potential for treating Tuberous Sclerosis Complex (TSC), a genetic disorder causing benign tumors and epilepsy, with promising early-phase results. Despite risks such as dependence on Ztalmy's performance, clinical trial uncertainties, and a competitive landscape, I recommend a 'Buy' for Marinus Pharmaceuticals due to its potential to disrupt the seizure disorder market.
Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade)
Marinus Pharmaceuticals has pivoted from postpartum depression to focus on seizure disorders, leading to FDA approval for Ztalmy (ganaxolone) for treating Cyclin-dependent Kinase-like 5 Deficiency Disorder (CDD) seizures. The company is exploring ganaxolone's potential for treating Tuberous Sclerosis Complex (TSC), a genetic disorder causing benign tumors and epilepsy, with promising early-phase results. Despite risks such as dependence on Ztalmy's performance, clinical trial uncertainties, and a competitive landscape, I recommend a 'Buy' for Marinus Pharmaceuticals due to its potential to disrupt the seizure disorder market.
05/11 09:56 EST - Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.52 per share a year ago.
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.52 per share a year ago.
05/03 07:01 EST - Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May. JMP Securities 2023 Life Sciences Conference in New York, NY May 15 at 3:30 p.m. E.T. RBC Annual Healthcare Conference in New York, NY May 16 at 10:00 a.m. E.T. Links to the events can be accessed on the Investor.
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May. JMP Securities 2023 Life Sciences Conference in New York, NY May 15 at 3:30 p.m. E.T. RBC Annual Healthcare Conference in New York, NY May 16 at 10:00 a.m. E.T. Links to the events can be accessed on the Investor.
04/27 07:01 EST - Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at i.
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at i.